Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00112463 · OUTCOME

Survival

Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma · Source last updated 2017-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Max of 98 months

What was measured

Months from first treatment until death or the last date of contact

Analysis population: All treated participants

Groups in this outcome

Treatment (Single-agent Depsipeptide)

Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Single-agent Depsipeptide)38

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Single-agent Depsipeptide)12.2Not reported7.619.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        7.6
        upper Limit
        19.3
        value
        12.2
denoms
  1. counts
    1. group Id
      OG000
      value
      38
    units
    Participants
description
Months from first treatment until death or the last date of contact
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.
    id
    OG000
    title
    Treatment (Single-agent Depsipeptide)
param Type
MEDIAN
population Description
All treated participants
reporting Status
POSTED
time Frame
Max of 98 months
title
Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice